Uroplakins and cytokeratins in the regenerating rat urothelium after sodium saccharin treatment.
A sodium saccharin (NaSac) diet was used to induce cell damage and regeneration in the urothelium of the male rat urinary bladder. Foci of terminally differentiated superficial cell exfoliation were detected after 5 weeks and their number increased after 10 and 15 weeks of the diet. At the sites of superficial cell loss, regenerative simple hyperplasia developed. Within 5 weeks of NaSac removal, regeneration re-established normal differentiated urothelium. In order to follow urothelial differentiation during regeneration we studied the expression of uroplakins and cytokeratins by means of immunocytochemistry and immunohistochemistry, respectively. Normal urothelium was characterised by terminally differentiated superficial cells which expressed uroplakins in their luminal plasma membrane and cytokeratin 20 (CK20) in the cytoplasm. Basal and intermediate cells were CK20 negative and cytokeratin 17 (CK17) positive. In hyperplastic urothelium all cells synthesised CK17, but not CK20. Differentiation of the superficial layer was reflected in three successive cell types: cells with microvilli, cells with rounded microridges and those with a rigid-looking plasma membrane on the luminal surface. The cells with microvilli did not stain with anti-uroplakin antibody. When the synthesis of uroplakins was detected rounded microridges were formed. With the elevated expression of uroplakins the luminal plasma membrane becomes rigid-looking which is characteristic of asymmetric unit membrane of terminally differentiated cells. During differentiation, synthesis of CK17 ceased in superficial cells while the synthesis of CK20 started. These results indicate that during urothelial regeneration after NaSac treatment, specific superficial cell types develop in which the switch to uroplakin synthesis and transition from CK17 to CK20 synthesis are crucial events for terminal differentiation.
Romih
R
R
Institute of Cell Biology, Medical Faculty, Ljubljana, Slovenia. romih@ibmi.mf.uni-lj.si
Jezernik
K
K
Masera
A
A
D000818:Animals; D002273:Carcinogens / Q000494:pharmacology; D007633:Keratins / Q000096:biosynthesis*; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D008565:Membrane Proteins / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration; D012439:Saccharin / Q000494:pharmacology*; D060170:Uroplakin II; D060171:Uroplakin III; D060169:Uroplakin Ib; D019459:Urothelium / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology
D002273:Carcinogens; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; C086452:UPK1B protein, human; C554658:UPK2 protein, human; D060170:Uroplakin II; D060171:Uroplakin III; D060169:Uroplakin Ib; D007633:Keratins; D012439:Saccharin